Antiplatelet effect of 2-(diethylamino)-7-hydroxychromone.
In this study the in vitro influence of 2-(diethylamino)-7-hydroxychromone (RC39II) on platelet aggregating responses, thromboxane A2 (TxA2) production, release reaction and intraplatelet cyclic AMP (cAMP) content has been investigated. The drug exerts a dose-dependent inhibitory effect on aggregating response to arachidonic acid, U46619, thrombin, collagen and calcium ionophore A23187. Inhibiting concentrations of RC39II also prevent platelet release reaction and TxA2 formation. RC39II potentiates platelet cAMP accumulation by Iloprost. Several studies, carried out on soluble cAMP phosphodiesterase (PDE) have shown that the drug inhibits phosphodiesterase in a dose-dependent manner. No effect was shown on adenylate cyclase activity from platelet membranes.
Leoncini
G
G
Istituto Policattedra di Chimica Biologica, Universita di Genova, Italy.
Maresca
M
M
Colao
C
C
Buzzi
E
E
Mazzei
M
M
Balbi
A
A
D001792:Blood Platelets / Q000378:metabolism; D000242:Cyclic AMP / Q000097:blood; D004305:Dose-Response Relationship, Drug; D006801:Humans; D066298:In Vitro Techniques; D010726:Phosphodiesterase Inhibitors; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors; D013928:Thromboxane A2 / Q000378:metabolism
D010726:Phosphodiesterase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013928:Thromboxane A2; D000242:Cyclic AMP